Elekta AB (EKTA.B) AI Stock Analysis

• Market Cap: kr19.09B
• Dividend Yield: 4.84%
• Average Volume (3M): 1.42M
• Price to Earnings (P/E): 80.9
• Beta (1Y): 0.95
• Revenue Growth: -0.57%
• EPS Growth: -81.68%
• Country: SE
• Employees: 4,541
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.11
• Shares Outstanding: 368,587,650
• 10 Day Avg. Volume: 1,784,341
• 30 Day Avg. Volume: 1,415,110
• PEG Ratio: 6.34
• Price to Book (P/B): 2.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 31.98
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr51.79
• Price Target Upside: 3.66% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 7

• Rating: 64 Neutral
• Price Target: kr54.00 ▲(8.09%Upside)

Elekta AB's stock score is influenced primarily by its solid financial performance, despite some cash flow constraints. Technical analysis suggests mixed signals with potential bearish trends, while the high P/E ratio indicates overvaluation. The decent dividend yield provides some support against valuation concerns.

Elekta AB Business Overview & Revenue Model

Company Description

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

How the Company Makes Money

Elekta AB generates revenue primarily through the sale and servicing of its medical devices and software solutions to hospitals and clinics worldwide. The company's key revenue streams include the sale of linear accelerators, which are used for radiation therapy, and associated software licenses for treatment planning and management. Elekta also earns revenue from long-term service agreements, offering maintenance and support for its equipment. Significant partnerships with healthcare providers and research institutions enhance its product offerings and market reach, contributing to its earnings. Additionally, Elekta's focus on innovation and technology advancements ensures a steady demand for its products in the oncology treatment space.

Elekta AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
17.88B	18.12B	16.87B	14.55B	13.76B	14.60B
	Gross Profit
6.52B	6.78B	6.35B	5.44B	5.61B	6.14B
	EBIT
1.78B	2.04B	1.43B	1.64B	1.91B	1.66B
	EBITDA
2.74B	3.29B	2.57B	2.74B	3.13B	2.99B
	Net Income Common Stockholders
1.04B	1.30B	943.00M	1.15B	1.25B	1.08B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.58B	2.78B	3.27B	3.07B	4.40B	6.46B
	Total Assets
32.95B	31.41B	29.61B	26.30B	24.84B	28.41B
	Total Debt
8.86B	7.25B	6.67B	5.70B	6.24B	9.36B
	Net Debt
5.28B	4.47B	3.40B	2.63B	1.84B	2.96B
	Total Liabilities
22.12B	20.63B	19.88B	17.39B	16.65B	20.30B
	Stockholders Equity
10.78B	10.77B	9.73B	8.91B	8.20B	8.11B
Cash Flow		Free Cash Flow
679.00M	817.00M	400.00M	450.00M	1.71B	252.00M
	Operating Cash Flow
2.38B	2.46B	1.96B	1.86B	2.55B	1.01B
	Investing Cash Flow
-1.80B	-1.92B	-1.61B	-1.65B	-613.00M	-1.30B
	Financing Cash Flow
516.00M	-1.10B	-129.00M	-1.73B	-3.60B	2.62B

Elekta AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 49.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EKTA.B, the sentiment is Negative. The current price of 49.96 is below the 20-day moving average (MA) of 51.00, below the 50-day MA of 50.34, and below the 200-day MA of 60.01, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 47.22 is Neutral, neither overbought nor oversold. The STOCH value of 32.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:EKTA.B.

Elekta AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	72 Outperform	€1.15B	35.49	10.11%	―	2.53%	-44.90%
EKTA.B	64 Neutral	kr19.09B	80.85	2.43%	4.84%	-0.57%	-81.68%
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
INTEG.B	53 Neutral	€430.95M	―	-19.17%	―	-12.50%	-783.92%
SEDANA	52 Neutral	kr1.21B	―	-5.61%	―	13.66%	-139.90%
ACARIX	46 Neutral	€255.30M	―	-88.97%	―	-0.61%	54.19%
HEART	34 Underperform	kr69.48M	―		―	―	―

Elekta AB Corporate Events

Elekta AB Reports Strong Q4 Performance with Best Gross Margin in Five Years

Elekta AB reported a 6% increase in net sales for the fourth quarter of 2024/25 at constant exchange rates, driven by strong performance in Europe and APAC, and a 3% increase in reported sales. The company achieved its best fourth-quarter gross margin in five years at 40.3%, supported by price increases, product launches, and a solid performance of its Elekta Evo linear accelerator and Elekta ONE software suite. Despite a non-cash impairment of SEK 1,064 M due to discontinued R&D projects, Elekta maintained a strong book-to-bill ratio and improved cash flow. The company expects continued sales growth and margin improvements, aiming to reach pre-pandemic levels, while its products have received positive feedback from healthcare providers.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK67.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta to Present Fiscal Year 2024/25 Developments

Elekta has announced a presentation for its fiscal year 2024/25, scheduled for May 28, where the company’s Acting President and CEO, Jonas Bolander, along with CFO Tobias Hägglöv, will discuss the company’s development. The event, which includes a live webcast and Q&A session, reflects Elekta’s commitment to transparency and engagement with analysts and investors, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK67.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.